Obesity - Pipeline Review, H2 2017

  • ID: 4429849
  • Drug Pipelines
  • 518 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Callitas Therapeutics Inc
  • FibroGen Inc
  • Juno Therapeutics Inc
  • Omeros Corp
  • Sanofi
  • MORE
Obesity - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Callitas Therapeutics Inc
  • FibroGen Inc
  • Juno Therapeutics Inc
  • Omeros Corp
  • Sanofi
  • MORE
Introduction

Obesity - Overview

Obesity - Therapeutics Development

Obesity - Therapeutics Assessment

Obesity - Companies Involved in Therapeutics Development

Obesity - Drug Profiles

Obesity - Dormant Projects

Obesity - Discontinued Products

Obesity - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Obesity, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Obesity - Pipeline by Abeome Corp, H2 2017

Obesity - Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Obesity - Pipeline by Aegis Therapeutics LLC, H2 2017

Obesity - Pipeline by Akron Molecules AG, H2 2017

Obesity - Pipeline by Amgen Inc, H2 2017

Obesity - Pipeline by Antag Therapeutics ApS, H2 2017

Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017

Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017

Obesity - Pipeline by AstraZeneca Plc, H2 2017

Obesity - Pipeline by Athersys Inc, H2 2017

Obesity - Pipeline by Biophytis SAS, H2 2017

Obesity - Pipeline by BioRestorative Therapies Inc, H2 2017

Obesity - Pipeline by Biozeus, H2 2017

Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Obesity - Pipeline by Braasch Biotech LLC, H2 2017

Obesity - Pipeline by C3J Therapeutics Inc, H2 2017

Obesity - Pipeline by Callitas Therapeutics Inc, H2 2017

Obesity - Pipeline by Carmot Therapeutics Inc, H2 2017

Obesity - Pipeline by Cereno Scientific AB, H2 2017

Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Obesity - Pipeline by CohBar Inc, H2 2017

Obesity - Pipeline by CoMentis Inc, H2 2017

Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017

Obesity - Pipeline by ConSynance Therapeutics Inc, H2 2017

Obesity - Pipeline by Corcept Therapeutics Inc, H2 2017

Obesity - Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Obesity - Pipeline by DiscoveryBiomed Inc, H2 2017

Obesity - Pipeline by Eisai Co Ltd, H2 2017

Obesity - Pipeline by Eli Lilly and Co, H2 2017

Obesity - Pipeline by Eternygen GmbH, H2 2017

Obesity - Pipeline by Evotec AG, H2 2017

Obesity - Pipeline by FibroGen Inc, H2 2017

Obesity - Pipeline by Genmedica Therapeutics SL, H2 2017

Obesity - Pipeline by Gila Therapeutics Inc, H2 2017

Obesity - Pipeline by Gilead Sciences Inc, H2 2017

Obesity - Pipeline by GlaxoSmithKline Plc, H2 2017

Obesity - Pipeline by Glucox Biotech AB, H2 2017

Obesity - Pipeline by HanAll Biopharma Co Ltd, H2 2017

Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by Immungenetics AG, H2 2017

Obesity - Pipeline by Intarcia Therapeutics Inc, H2 2017

Obesity - Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Obesity - Pipeline by Ixchel Pharma LLC, H2 2017

Obesity - Pipeline by Johnson & Johnson, H2 2017

Obesity - Pipeline by Juno Therapeutics Inc, H2 2017

Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by Laboratorios Silanes SA de CV, H2 2017

Obesity - Pipeline by Lead Discovery Center GmbH, H2 2017

Obesity - Pipeline by Leading BioSciences Inc, H2 2017

Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by Magnus Life Ltd, H2 2017

Obesity - Pipeline by MedImmune LLC, H2 2017

Obesity - Pipeline by Merck & Co Inc, H2 2017

Obesity - Pipeline by Naia Ltd, H2 2017

Obesity - Pipeline by NeuroNano Pharma Inc, H2 2017

Obesity - Pipeline by NGM Biopharmaceuticals Inc, H2 2017

Obesity - Pipeline by NIBEC, H2 2017

Obesity - Pipeline by Nordic Bioscience A/S, H2 2017

Obesity - Pipeline by Novartis AG, H2 2017

Obesity - Pipeline by Novo Nordisk AS, H2 2017

Obesity - Pipeline by ObeTherapy Biotechnology, H2 2017

Obesity - Pipeline by Omeros Corp, H2 2017

Obesity - Pipeline by OPKO Biologics Ltd, H2 2017

Obesity - Pipeline by OPKO Health Inc, H2 2017

Obesity - Pipeline by Oramed Pharmaceuticals Inc, H2 2017

Obesity - Pipeline by Orexigen Therapeutics Inc, H2 2017

Obesity - Pipeline by Palatin Technologies Inc, H2 2017

Obesity - Pipeline by Pfizer Inc, H2 2017

Obesity - Pipeline by PharmaIN Corp, H2 2017

Obesity - Pipeline by Poxel SA, H2 2017

Obesity - Pipeline by Prometheon Pharma LLC, H2 2017

Obesity - Pipeline by ReCyte Therapeutics Inc, H2 2017

Obesity - Pipeline by Renova Therapeutics Inc, H2 2017

Obesity - Pipeline by Reviva Pharmaceuticals Inc, H2 2017

Obesity - Pipeline by Saniona AB, H2 2017

Obesity - Pipeline by Sanofi, H2 2017

Obesity - Pipeline by Seres Therapeutics Inc, H2 2017

Obesity - Pipeline by Shionogi & Co Ltd, H2 2017

Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by Sorrento Therapeutics Inc, H2 2017

Obesity - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by Toray Industries Inc, H2 2017

Obesity - Pipeline by Vicore Pharma AB, H2 2017

Obesity - Pipeline by Viking Therapeutics Inc, H2 2017

Obesity - Pipeline by Vivus Inc, H2 2017

Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017

Obesity - Pipeline by XL-protein GmbH, H2 2017

Obesity - Pipeline by Yuyu Pharma Inc, H2 2017

Obesity - Pipeline by Zafgen Inc, H2 2017

Obesity - Pipeline by Zealand Pharma AS, H2 2017

Obesity - Dormant Projects, H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..1), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..2), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..3), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..4), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..5), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..6), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..7), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..8), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..9), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..10), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..11), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..12), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..13), H2 2017

Obesity - Dormant Projects, H2 2017 (Contd..14), H2 2017

Obesity - Discontinued Products, H2 2017

Obesity - Discontinued Products, H2 2017 (Contd..1), H2 2017

Obesity - Discontinued Products, H2 2017 (Contd..2), H2 2017

Obesity - Discontinued Products, H2 2017 (Contd..3), H2 2017

List of Figures

Number of Products under Development for Obesity, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abeome Corp
  • Adamas Pharmaceuticals Inc
  • Aegis Therapeutics LLC
  • Akron Molecules AG
  • Amgen Inc
  • Antag Therapeutics ApS
  • Aoxing Pharmaceutical Company Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Biophytis SAS
  • BioRestorative Therapies Inc
  • Biozeus
  • Boehringer Ingelheim GmbH
  • Braasch Biotech LLC
  • C3J Therapeutics Inc
  • Callitas Therapeutics Inc
  • Carmot Therapeutics Inc
  • Cereno Scientific AB
  • Chong Kun Dang Pharmaceutical Corp
  • CohBar Inc
  • CoMentis Inc
  • Connexios Life Sciences Pvt Ltd
  • ConSynance Therapeutics Inc
  • Corcept Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • DiscoveryBiomed Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Eternygen GmbH
  • Evotec AG
  • FibroGen Inc
  • Genmedica Therapeutics SL
  • Gila Therapeutics Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Immungenetics AG
  • Intarcia Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Ixchel Pharma LLC
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kissei Pharmaceutical Co Ltd
  • Laboratorios Silanes SA de CV
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Lotus Pharmaceutical Co Ltd
  • Magnus Life Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Naia Ltd
  • NeuroNano Pharma Inc
  • NGM Biopharmaceuticals Inc
  • NIBEC
  • Nordic Bioscience A/S
  • Novartis AG
  • Novo Nordisk AS
  • ObeTherapy Biotechnology
  • Omeros Corp
  • OPKO Biologics Ltd
  • OPKO Health Inc
  • Oramed Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • Palatin Technologies Inc
  • Pfizer Inc
  • PharmaIN Corp
  • Poxel SA
  • Prometheon Pharma LLC
  • ReCyte Therapeutics Inc
  • Renova Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Saniona AB
  • Sanofi
  • Seres Therapeutics Inc
  • Shionogi & Co Ltd
  • Sinil Pharmaceutical Co Ltd
  • Sorrento Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Toray Industries Inc
  • Vicore Pharma AB
  • Viking Therapeutics Inc
  • Vivus Inc
  • WhanIn Pharmaceutical Co Ltd
  • XL-protein GmbH
  • Yuyu Pharma Inc
  • Zafgen Inc
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll